Simple and efficient model systems of screening anti-Toxoplasma drugs in vitro

Bibliography

• Dubey JP. Toxoplasmosis in sheep-the last 20 years. Vet Parasitol 2009;163(1-2):1-14
   PubMed Web of Science ®Google Scholar
• Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000;30(12-13):1217-58
   PubMed Web of Science ®Google Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004;363(9425):1965-76
   PubMed Web of Science ®Google Scholar
• Dunn D, Wallon M, Peyron F, Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999;353(9167):1829-33
   PubMed Web of Science ®Google Scholar
• Sabin AB, Warren J. Therapeutic effectiveness of certain sulfonamide on infection by an intracellular protozoon (Toxoplasma). Proc Soc Exp Biol Med 1942;51:19-23
   Google Scholar
• Burnett AJ, Shortt SG, Isaac-Renton J, Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology 1998;105(6):1032-7
   PubMed Web of Science ®Google Scholar
• Bedu-Addo G. Cerebral toxoplasmosis in HIV/AIDS: a case report. West Afr J Med 2006;25(3):252-3
   PubMedGoogle Scholar
• Alappat JP, Mathew CF, Jayakumar K, A case of cerebral toxoplasmosis. Neurol India 2000;48(2):185-7
   PubMed Web of Science ®Google Scholar
• Eyles DE, Coleman N. Synergistic effect of sulfadiazine and daraprim against experimental toxoplasmosis in the mouse. Antibiot Chemother 1953;3:483-90
   Google Scholar
• Remington JS, McLeod R, Thulliez P, Toxoplasmosis. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th edition. W B Saunders; Philadelphia, PA: 2006. p 947-91
   Google Scholar
• Garin JP, Eyles ED. Le traitement de la toxoplasmose experimentale de la souris par la spiramycine. La Presse Med 1958;66:957-8
   PubMed Web of Science ®Google Scholar
• Desmonts G, Couvreur J. Toxoplasmosis in pregnancy and its transmission to the fetus. Bull NY Acad Med 1974;50(2):146-59
   PubMedGoogle Scholar
• McMaster PR, Powers KG, Finerty JF, The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. Am J Trop Med Hyg 1973;22(1):14-17
   PubMed Web of Science ®Google Scholar
• Araujo FG, Remington JS. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother 1974;5(6):647-51
   PubMed Web of Science ®Google Scholar
• Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15(2):211-22
   PubMed Web of Science ®Google Scholar
• Georgiev VS. Management of toxoplasmosis. Drugs 1994;48(2):179-88
   PubMed Web of Science ®Google Scholar
• Dannemann B, McCutchan JA, Israelski D, Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992;116(1):33-43
   PubMed Web of Science ®Google Scholar
• Raffi F, Struillou L, Ninin E, Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. Clin Infect Dis 1995;20(4):1076-7
   PubMed Web of Science ®Google Scholar
• Godofsky EW. Treatment of presumed cerebral toxoplasmosis with azithromycin. N Engl J Med 1994;330(8):575-6
   PubMed Web of Science ®Google Scholar
• Farthing C, Rendel M, Currie B, Azithromycin for cerebral toxoplasmosis. Lancet 1992;339(8790):437-8
   PubMed Web of Science ®Google Scholar
• Wynn RF, Leen CL, Brettle RP. Azithromycin for cerebral toxoplasmosis in AIDS. Lancet 1993;341(8839):243-4
   PubMed Web of Science ®Google Scholar
• Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992;340(8820):637-8
   PubMed Web of Science ®Google Scholar
• Pijpers E, van Rijswijk RE, Takx-Kohlen B, A clarithromycin-induced myasthenic syndrome. Clin Infect Dis 1996;22(1):175-6
   PubMed Web of Science ®Google Scholar
• Dvorak JA, Howe CL. Toxoplasma gondii-vertebrate cell interactions. I. The influence of bicarbonate ion, CO2, pH and host cell culture age on the invasion of vertebrate cells in vitro. J Protozool 1977;24(3):416-19
   PubMedGoogle Scholar
• de Araujo Jorge TC, de Souza W. Effect of carbohydrates, periodate and enzymes in the process of endocytosis of Trypanosoma cruzi by macrophages. Acta Trop 1984;41(1):17-28
   PubMed Web of Science ®Google Scholar
• Endoh T, Yagita K. Toxoplasma gondii: a simple method for titration of infectivity with monolayer cells. Jpn J Med Sci Biol 1989;42(1):13-23
   PubMedGoogle Scholar
• Nakao M, Konishi E. Proliferation of Toxoplasma gondii in human neutrophils in vitro. Parasitology 1991;103(Pt 1):23-7
   PubMedGoogle Scholar
• Benedetto N, Folgore A, Ferrara C, Effects of alpha-adrenergic agonists on Toxoplasma gondii replication in human umbilical vein endothelial cells. Pathol Biol (Paris) 1997;45(1):9-18
   PubMed Web of Science ®Google Scholar
• Song HO, Ahn MH, Ryu JS, Influence of calcium ion on host cell invasion and intracellular replication by Toxoplasma gondii. Korean J Parasitol 2004;42(4):185-93
   PubMedGoogle Scholar
• Martins-Duarte ES, Urbina JA, de Souza W, Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro. J Antimicrob Chemother 2006;58(1):59-65
   PubMed Web of Science ®Google Scholar
• Jin C, Kaewintajuk K, Jiang J, Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro. Exp Parasitol 2009;121(2):132-6
   PubMed Web of Science ®Google Scholar
• Beaman MH, Hunter CA, Remington JS. Enhancement of intracellular replication of Toxoplasma gondii by IL-6. Interactions with IFN-gamma and TNF-alpha. J Immunol 1994;153(10):4583-7
   PubMed Web of Science ®Google Scholar
• Peterson PK, Gekker G, Hu S, Intracellular survival and multiplication of Toxoplasma gondii in astrocytes. J Infect Dis 1993;168(6):1472-8
   PubMed Web of Science ®Google Scholar
• Omata Y, Kawano T, Ohsawa T, Infectivity of feline enteroepithelial stages of Toxoplasma gondii isolated by Percoll-density gradient centrifugation. Vet Parasitol 1999;82(3):211-15
   PubMed Web of Science ®Google Scholar
• Tanaka T, Omata Y, Saito A, Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites. Exp Parasitol 1995;81(4):614-17
   PubMed Web of Science ®Google Scholar
• Pelloux H, Pernod G, Polack B, Influence of cytokines on Toxoplasma gondii growth in human astrocytoma-derived cells. Parasitol Res 1996;82(7):598-603
   PubMed Web of Science ®Google Scholar
• Nagineni CN, Pardhasaradhi K, Martins MC, Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun 1996;64(10):4188-96
   PubMed Web of Science ®Google Scholar
• Soete M, Fortier B, Camus D, Toxoplasma gondii: kinetics of bradyzoite-tachyzoite interconversion in vitro. Exp Parasitol 1993;76(3):259-64
   PubMed Web of Science ®Google Scholar
• Chao CC, Gekker G, Hu S, Human microglial cell defense against Toxoplasma gondii. The role of cytokines. J Immunol 1994;152(3):1246-52
   PubMed Web of Science ®Google Scholar
• Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis 1991;164(1):170-1
   PubMed Web of Science ®Google Scholar
• McFadden DC, Seeber F, Boothroyd JC. Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob Agents Chemother 1997;41(9):1849-53
   PubMed Web of Science ®Google Scholar
• Araujo FG, Khan AA, Slifer TL, The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob Agents Chemother 1997;41(10):2137-40
   PubMed Web of Science ®Google Scholar
• Mineo JR, Khan IA, Kasper LH. Toxoplasma gondii: a monoclonal antibody that inhibits intracellular replication. Exp Parasitol 1994;79(3):351-61
   PubMed Web of Science ®Google Scholar
• Woodman JP, Dimier IH, Bout DT. Human endothelial cells are activated by IFN-gamma to inhibit Toxoplasma gondii replication. Inhibition is due to a different mechanism from that existing in mouse macrophages and human fibroblasts. J Immunol 1991;147(6):2019-23
   PubMed Web of Science ®Google Scholar
• McLeod R, Remington JS. A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen. J Immunol Methods 1979;27(1):19-29
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER, Pfefferkorn LC. Specific labeling of intracellular Toxoplasma gondii with uracil. J Protozool 1977;24(3):449-53
   PubMedGoogle Scholar
• Merli A, Canessa A, Melioli G. Enzyme immunoassay for evaluation of Toxoplasma gondii growth in tissue culture. J Clin Microbiol 1985;21(1):88-91
   PubMed Web of Science ®Google Scholar
• Derouin F, Chastang C. Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture. Antimicrob Agents Chemother 1988;32(3):303-7
   PubMed Web of Science ®Google Scholar
• Seeber F, Boothroyd JC. Escherichia coli beta-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene 1996;Feb169(1):39-45
   PubMed Web of Science ®Google Scholar
• Kropf C, Debache K, Rampa C, The adaptive potential of a survival artist: characterization of the in vitro interactions of Toxoplasma gondii tachyzoites with di-cationic compounds in human fibroblast cell cultures. Parasitology 2011;1-13 Available on CJO 2011 doi:10.1017/S0031182011001776
   Google Scholar
• Cozon G, Roure C, Lizard G, An improved assay for the detection of Toxoplasma gondii antibodies in human serum by flow cytometry. Cytometry 1993;14(5):569-75
   PubMedGoogle Scholar
• Peyron F, Favel A, Guiraud-Dauriac H, Evaluation of a flow cytofluorometric method for rapid determination of amphotericin B susceptibility of yeast isolates. Antimicrob Agents Chemother 1997;41(7):1537-40
   PubMed Web of Science ®Google Scholar
• Gay-Andrieu F, Cozon GJ, Ferrandiz J, Flow cytometric quantification of Toxoplasma gondii cellular infection and replication. J Parasitol 1999;85(3):545-9
   PubMed Web of Science ®Google Scholar
• Tsien RY. The green fluorescent protein. Annu Rev Biochem 1998;67:509-44
   PubMed Web of Science ®Google Scholar
• Pelletier L, Stern CA, Pypaert M, Golgi biogenesis in Toxoplasma gondii. Nature 2002;418(6897):548-52
   PubMed Web of Science ®Google Scholar
• Hu K, Mann T, Striepen B, Daughter cell assembly in the protozoan parasite Toxoplasma gondii. Mol Biol Cell 2002;13(2):593-606
   PubMed Web of Science ®Google Scholar
• Hu K, Roos DS, Murray JM. A novel polymer of tubulin forms the conoid of Toxoplasma gondii. J Cell Biol 2002;156(6):1039-50
   PubMed Web of Science ®Google Scholar
• Striepen B, Soldati D, Garcia-Reguet N, Targeting of soluble proteins to the rhoptries and micronemes in Toxoplasma gondii. Mol Biochem Parasitol 2001;113(1):45-53
   PubMed Web of Science ®Google Scholar
• Striepen B, Crawford MJ, Shaw MK, The plastid of Toxoplasma gondii is divided by association with the centrosomes. J Cell Biol 2000;151(7):1423-34
   PubMed Web of Science ®Google Scholar
• Striepen B, He CY, Matrajt M, Expression, selection, and organellar targeting of the green fluorescent protein in Toxoplasma gondii. Mol Biochem Parasitol 1998;92(2):325-38
   PubMed Web of Science ®Google Scholar
• Carey KL, Westwood NJ, Mitchison TJ, A small-molecule approach to studying invasive mechanisms of Toxoplasma gondii. Proc Natl Acad Sci USA 2004;101(19):7433-8
   PubMed Web of Science ®Google Scholar
• Gubbels MJ, Li C, Striepen B. High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein. Antimicrob Agents Chemother 2003;47(1):309-16
   PubMed Web of Science ®Google Scholar
• Cubitt AB, Woollenweber LA, Heim R. Understanding structure-function relationships in the Aequorea victoria green fluorescent protein. Methods Cell Biol 1999;58:19-30
   PubMed Web of Science ®Google Scholar
• Chio LC, Queener SF. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother 1993;37(9):1914-23
   PubMed Web of Science ®Google Scholar
• Gangjee A, Adair OO, Pagley M, N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem 2008;51(19):6195-200
   PubMed Web of Science ®Google Scholar
• Mui EJ, Schiehser GA, Milhous WK, Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis 2008;2(3):e190
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Fu H, Chan DC, Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpt eridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. J Med Chem 2004;47(10):2475-85
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Chen H, Fu H, Queener SF. Synthesis of new 2,4-Diaminopyrido[2,3-d]pyrimidine and 2,4-Diaminopyrrolo[2,3-d]pyrimidine inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. Bioorg Med Chem 2003;11(1):59-67
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Forsch RA, Queener SF. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. J Med Chem 2002;45(1):233-41
   PubMed Web of Science ®Google Scholar
• Gangjee A, Adair O, Queener SF. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines. J Med Chem 1999;42(13):2447-55
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Papoulis AT, Queener SF. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem 1998;41(6):913-18
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Papoulis AT, Queener SF. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem 1997;40(22):3694-9
   PubMed Web of Science ®Google Scholar
• Gangjee A, Vasudevan A, Queener SF. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii. J Med Chem 1997;40(19):3032-9
   PubMed Web of Science ®Google Scholar
• Gangjee A, Devraj R, Queener SF. Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates. J Med Chem 1997;40(4):470-8
   PubMed Web of Science ®Google Scholar
• Jackson HC, Biggadike K, McKilligin E, 6,7-Disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother 1996;40(6):1371-5
   PubMed Web of Science ®Google Scholar
• Gangjee A, Zhu Y, Queener SF, Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii. J Med Chem 1996;39(9):1836-45
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Forsch RA, Queener SF. 2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. J Med Chem 1995;38(14):2615-20
   PubMed Web of Science ®Google Scholar
• Gangjee A, Vasudevan A, Queener SF, 6-Substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. J Med Chem 1995;38(10):1778-85
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Mota CE, Wright JE, 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem 1993;36(21):3103-12
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Queener SF, Cody V. Inhibition of dihydrofolate reductases from Toxoplasma gondii, Pneumocystis carinii, and rat liver by rotationally restricted analogues of pyrimethamine and metoprine. Drug Des Discov 1999;16(1):25-40
   PubMedGoogle Scholar
• Ajzenberg D, Yera H, Marty P, Genotype of 88 Toxoplasma gondii isolates associated with toxoplasmosis in immunocompromised patients and correlation with clinical findings. J Infect Dis 2009;199(8):1155-67
   PubMed Web of Science ®Google Scholar
• Ajzenberg D, Cogne N, Paris L, Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. J Infect Dis 2002;186(5):684-9
   PubMed Web of Science ®Google Scholar
• Zhou P, Sun XT, Yin CC, Genetic characterization of Toxoplasma gondii isolates from pigs in Southwestern China. J Parasitol 2011;97(6):1193-5
   PubMed Web of Science ®Google Scholar
• Boughattas S, Abdallah RB, Siala E, An atypical strain associated with congenital toxoplasmosis in Tunisia. New Microbiol 2011;34(4):413-16
   PubMed Web of Science ®Google Scholar
• Fekkar A, Ajzenberg D, Bodaghi B, Direct genotyping of Toxoplasma gondii in ocular fluid samples from 20 patients with ocular toxoplasmosis: predominance of type 2 in France. J Clin Microbiol 2011;49(4):1513-17
   PubMed Web of Science ®Google Scholar
• Frazao-Teixeira E, Sundar N, Dubey JP, Multi-locus DNA sequencing of Toxoplasma gondii isolated from Brazilian pigs identifies genetically divergent strains. Vet Parasitol 2011;175(1-2):33-9
   PubMed Web of Science ®Google Scholar
• Dubey JP, Rajendran C, Costa DG, New Toxoplasma gondii genotypes isolated from free-range chickens from the Fernando de Noronha, Brazil: unexpected findings. J Parasitol 2010;96(4):709-12
   PubMed Web of Science ®Google Scholar
• Dubey JP, Rajendran C, Ferreira LR, A new atypical highly mouse virulent Toxoplasma gondii genotype isolated from a wild black bear in Alaska. J Parasitol 2010;96(4):713-16
   PubMed Web of Science ®Google Scholar
• Boughattas S, Ben-Abdallah R, Siala E, Direct genotypic characterization of Toxoplasma gondii strains associated with congenital toxoplasmosis in Tunisia (North Africa). Am J Trop Med Hyg 2010;82(6):1041-6
   PubMed Web of Science ®Google Scholar
• Al-Kappany YM, Rajendran C, Abu-Elwafa SA, Genetic diversity of Toxoplasma gondii isolates in Egyptian feral cats reveals new genotypes. J Parasitol 2010;96(6):1112-14
   PubMed Web of Science ®Google Scholar
• Ajzenberg D. Type 1 strains in human toxoplasmosis: myth or reality? Future Microbiol 2010;5(6):841-3
   PubMed Web of Science ®Google Scholar
• Ong YC, Reese ML, Boothroyd JC. Toxoplasma rhoptry protein 16 (ROP16) subverts host function by direct tyrosine phosphorylation of STAT6. J Biol Chem 2010;285(37):28731-40
   PubMed Web of Science ®Google Scholar
• Peixoto L, Chen F, Harb OS, Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe 2010;8(2):208-18
   PubMed Web of Science ®Google Scholar
• Khan A, Taylor S, Ajioka JW, Selection at a single locus leads to widespread expansion of Toxoplasma gondii lineages that are virulent in mice. PLoS Genet 2009;5(3):e1000404
   PubMedGoogle Scholar
• Yamamoto M, Standley DM, Takashima S, A single polymorphic amino acid on Toxoplasma gondii kinase ROP16 determines the direct and strain-specific activation of Stat3. J Exp Med 2009;206(12):2747-60
   PubMed Web of Science ®Google Scholar
• Saeij JP, Coller S, Boyle JP, Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature 2007;445(7125):324-7
   PubMed Web of Science ®Google Scholar
• Saeij JP, Boyle JP, Coller S, Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Science 2006;314(5806):1780-3
   PubMed Web of Science ®Google Scholar
• Taylor S, Barragan A, Su C, A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 2006;314(5806):1776-80
   PubMed Web of Science ®Google Scholar
• Khan A, Taylor S, Su C, Composite genome map and recombination parameters derived from three archetypal lineages of Toxoplasma gondii. Nucleic Acids Res 2005;33(9):2980-92
   PubMed Web of Science ®Google Scholar
• Sicard O, Loudet O, Keurentjes JJ, Identification of quantitative trait loci controlling symptom development during viral infection in Arabidopsis thaliana. Mol Plant Microbe Interact 2008;21(2):198-207
   PubMed Web of Science ®Google Scholar
• Dube A, Gupta R, Singh N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 2009;25(9):432-9
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Uppuluri P, Lopez-Ribot J, Development of a high-throughput Candida albicans biofilm chip. PLoS One 2011;6(4):e19036
   PubMed Web of Science ®Google Scholar